WO2010057449A3 - A solid pharmaceutical composition with atorvastatin and telmisartan as the active substances - Google Patents

A solid pharmaceutical composition with atorvastatin and telmisartan as the active substances Download PDF

Info

Publication number
WO2010057449A3
WO2010057449A3 PCT/CZ2009/000138 CZ2009000138W WO2010057449A3 WO 2010057449 A3 WO2010057449 A3 WO 2010057449A3 CZ 2009000138 W CZ2009000138 W CZ 2009000138W WO 2010057449 A3 WO2010057449 A3 WO 2010057449A3
Authority
WO
WIPO (PCT)
Prior art keywords
weight
composition
atorvastatin
telmisartan
smaller
Prior art date
Application number
PCT/CZ2009/000138
Other languages
French (fr)
Other versions
WO2010057449A2 (en
Inventor
Alena Prokopova
Jan Linek
Eva Gryczova
Original Assignee
Zentiva, K.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva, K.S. filed Critical Zentiva, K.S.
Publication of WO2010057449A2 publication Critical patent/WO2010057449A2/en
Publication of WO2010057449A3 publication Critical patent/WO2010057449A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A solid pharmaceutical composition with the active substances telmisartan and atorvastatin, characterized by in that both the substances are in the form of alkali or alkaline earth salts and the composition further contains an organic or inorganic base selected from the substances meglumine, sodium or potassium hydroxide, calcium or magnesium or sodium or potassium hydroxide, oxide or carbonate, and further polyvinyl pyrrolidone and a filler selected either from: a) a mono- or oligosaccharide soluble in water, or an alcoholic sugar, the size of 95% by weight of all particles of the filler, which may be present in the composition either individually or combined in larger granules, 99% by weight of which are smaller than 1.0 mm, being in the range of 0.025 to 0.355 mm; b) or a polysaccharide insoluble in water, 95% by weight of all particles of the filler, which may be present in the composition either individually or combined in large granules, 75% by weight of which are smaller than 0.50 mm, being smaller than 0.25 mm.
PCT/CZ2009/000138 2008-11-24 2009-11-16 A solid pharmaceutical composition with atorvastatin and telmisartan as the active substances WO2010057449A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ20080740A CZ2008740A3 (en) 2008-11-24 2008-11-24 Solid pharmaceutical composition with atorvastatin and telmisartan active ingredients
CZPV2008-740 2008-11-24

Publications (2)

Publication Number Publication Date
WO2010057449A2 WO2010057449A2 (en) 2010-05-27
WO2010057449A3 true WO2010057449A3 (en) 2011-03-17

Family

ID=41462928

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CZ2009/000138 WO2010057449A2 (en) 2008-11-24 2009-11-16 A solid pharmaceutical composition with atorvastatin and telmisartan as the active substances

Country Status (2)

Country Link
CZ (1) CZ2008740A3 (en)
WO (1) WO2010057449A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101248804B1 (en) * 2010-05-14 2013-03-29 한미사이언스 주식회사 BILAYERED PHARMACEUTICAL COMPOSITION OF HMG-CoA REDUCTASE INHIBITOR AND IRBESARTAN
WO2014068507A1 (en) * 2012-11-02 2014-05-08 Abbott Healthcare Pvt. Ltd. Solid oral pharmaceutical compositions of telmisartan, essentially free of surfactants
CN106176658A (en) * 2016-06-29 2016-12-07 扬子江药业集团四川海蓉药业有限公司 A kind of atorvastatin and preparation method thereof
WO2019130049A1 (en) 2017-12-29 2019-07-04 Grünenthal GmbH Pharmaceutical combination comprising extended-release tramadol hydrochloride and immediate-release etoricoxib, and its use for the treatment of pain

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2513277A1 (en) * 2003-01-16 2004-07-29 Boehringer Ingelheim International Gmbh Pharmaceutical combination for the prevention or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases
US20060078615A1 (en) * 2004-10-12 2006-04-13 Boehringer Ingelheim International Gmbh Bilayer tablet of telmisartan and simvastatin
WO2007061415A1 (en) * 2005-11-22 2007-05-31 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions of telmisartan
WO2008054123A1 (en) * 2006-10-30 2008-05-08 Hanall Pharmaceutical Company, Ltd. Controlled release complex composition comprising angiotensin-ii-receptor blockers and hmg-coa reductase inhibitors
WO2008068217A2 (en) * 2006-12-04 2008-06-12 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a coated hmg-coa reductase inhibitor and an inhibitor of the renin-angiotensin system
WO2008106901A1 (en) * 2007-03-02 2008-09-12 Zentiva, A.S. A pharmaceutical composition with atorvastatin active ingredient

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026188A1 (en) 1994-03-29 1995-10-05 Merck & Co., Inc. Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles
GT199800126A (en) * 1997-08-29 2000-01-29 COMBINATION THERAPY.
EP1514543A1 (en) * 1997-08-29 2005-03-16 Pfizer Inc. Combination therapy comprising atorvastatin and an antihypertensive agent
DK1854454T3 (en) 2002-01-16 2014-01-13 Boehringer Ingelheim Pharma Process for the preparation of amorphous telmisartan
DE10319450A1 (en) 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical formulation of telmisartan sodium salt
SE526257C2 (en) * 2003-12-22 2005-08-09 Operax Ab Forwarding quality control method in data network, involves combining end-to-end measurements and network routing topology information into information set, to detect correlated and uncorrelated paths
ES2452019T5 (en) 2004-11-05 2021-06-28 Boehringer Ingelheim Int Bilayer tablet comprising telmisartan and amlodipine
US8637078B2 (en) 2005-11-24 2014-01-28 Boehringer Ingelheim International Gmbh Bilayer tablet comprising telmisartan and diuretic

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2513277A1 (en) * 2003-01-16 2004-07-29 Boehringer Ingelheim International Gmbh Pharmaceutical combination for the prevention or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases
US20060078615A1 (en) * 2004-10-12 2006-04-13 Boehringer Ingelheim International Gmbh Bilayer tablet of telmisartan and simvastatin
WO2007061415A1 (en) * 2005-11-22 2007-05-31 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions of telmisartan
WO2008054123A1 (en) * 2006-10-30 2008-05-08 Hanall Pharmaceutical Company, Ltd. Controlled release complex composition comprising angiotensin-ii-receptor blockers and hmg-coa reductase inhibitors
WO2008068217A2 (en) * 2006-12-04 2008-06-12 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a coated hmg-coa reductase inhibitor and an inhibitor of the renin-angiotensin system
WO2008106901A1 (en) * 2007-03-02 2008-09-12 Zentiva, A.S. A pharmaceutical composition with atorvastatin active ingredient

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RAYMOND C R, P J SHESKEY & S C OWEN: "Handbook of pharmaceutical excipients, 5th edition", 2006, PHARMACEUTICAL PRESS, XP002608512 *

Also Published As

Publication number Publication date
WO2010057449A2 (en) 2010-05-27
CZ301299B6 (en) 2010-01-06
CZ2008740A3 (en) 2010-01-06

Similar Documents

Publication Publication Date Title
WO2009004512A3 (en) Solidification matrix including a salt of a straight chain saturated mono-, di-, or tri- carboxylic acid
CL2013001586A1 (en) Rapid dispersion microgranular composition comprising at least one sugar alcohol, a saccharide, or a mixture thereof, at least one super disintegrant and at least one multifunctional additive; oral disintegration tablet comprising the microgranular composition and at least one active ingredient; and manufacturing methods.
MY156436A (en) A novel water dispersible granular composition
TN2009000093A1 (en) Pharmaceutical compositions comprising nilotinib or its salt
EP1932530A4 (en) Agent for enhancing collagen production and utilization of the same
IL309564A (en) Apixaban formulations
WO2011061654A3 (en) Solidification matrix using a maleic-containing terpolymer binding agent
EP2210591A3 (en) Wet granulation tableting method using aqueous dispersion of low-substituted hydroxypropyl cellulose
WO2010057036A3 (en) Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low ph and methods of use thereof
WO2011053003A3 (en) Gastric-retentive sustained release formulation containing pregabalin, polyethyleneoxide and pva-peg graft copolymer
WO2009063222A3 (en) Solid compositions
EP1842572A3 (en) Hair cleansing composition
IN2012DN05020A (en)
WO2011061655A3 (en) Solidification matrix using a sulfonated/carboxylated polymer binding agent
NZ589517A (en) A pharmaceutical composition comprising rebamipide
UA103025C2 (en) Solid pharmaceutical formulation with delayed release
WO2009038112A1 (en) Solid preparation comprising npyy5 receptor antagonist
WO2010057449A3 (en) A solid pharmaceutical composition with atorvastatin and telmisartan as the active substances
WO2010038237A3 (en) Compositions exhibiting delayed transit through the gastrointestinal tract
MX2015008704A (en) Solid tablet unit dose oven cleaner.
WO2008100240A3 (en) Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same
MX340436B (en) Stable pharmaceutical formulation with limited discoloration.
UA101983C2 (en) Telmisartan tablets
EP1935417A4 (en) Composition for use in prevention of hypoglycemic condition
EA201070806A1 (en) COMPOSITION OF SLOW-FINGING ON THE BASIS OF THE ASSOCIATION OF GLYCOGEN AND ALGINATE

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09801378

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09801378

Country of ref document: EP

Kind code of ref document: A2